|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue (Note 14) | |||||
| Cost of revenue (Note 15) | |||||
| Gross profit | |||||
| Operating expenses | |||||
| General and administrative | |||||
| Sales and marketing | |||||
| Research and development | |||||
| Share-based compensation (Note 12) | |||||
| Foreign exchange loss (gain) | |||||
| Depreciation and amortization (Note 5, 6 and 7) | |||||
| Operating expenses | |||||
| Operating income | |||||
| Finance income, net (Note 9) | |||||
| Other income, net | |||||
| Income before income taxes | |||||
| Income tax (recovery) expense (Note 17) | |||||
| Net income | |||||
| Other comprehensive income | |||||
| Item that may be reclassified subsequently to income: | |||||
| Exchange (gain) loss on translation of foreign operations | |||||
| Actuarial gain (Note 10) | |||||
| Other comprehensive income | |||||
| Comprehensive income | |||||
| Earnings per share - basic (Note 12) (in dollars per share) | |||||
| Earnings per share - diluted (Note 12) (in dollars per share) | |||||
| Weighted average number of common shares outstanding - basic (Note 12) (in shares) | |||||
| Weighted average number of common shares outstanding - diluted (Note 12) (in shares) | |||||
Loading...
